• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Orthofix Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement

    4/7/25 4:48:02 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care
    Get the next $OFIX alert in real time by email
    8-K
    false000088462400008846242025-04-012025-04-01

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): April 01, 2025

     

     

    ORTHOFIX MEDICAL INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    000-19961

    98-1340767

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    3451 Plano Parkway

     

    Lewisville, Texas

     

    75056

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (214) 937-2000

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common stock, $0.10 par value per share

     

    OFIX

     

    Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 1.01 Entry into a Material Definitive Agreement.

    On April 1, 2025, Orthofix Medical Inc. (the “Company”) became tenant under a new lease governing its Carlsbad, California office location (5770 Armada Drive) (the “New Lease”), which became effective on such date. The Company had previously been tenant pursuant to a prior sublease with respect to such location (which is filed as Exhibit 10.12 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024), which sublease terminated as of such date.

    The New Lease provides for a term through October 31, 2037. The Company’s monthly rent, which includes 3.5% annual increases, is estimated to have a total pre-tax occupancy cost of approximately $34.6 million over the 12.5 year term of the lease. In addition to monthly rent, the Company is also obligated to pay the real estate taxes, insurance costs and utility and other expenses for the property.

    Item 1.02 Termination of a Material Definitive Agreement.

    The disclosure contained in Item 1.01 with respect to the termination of the Company’s prior lease is incorporated herein by reference.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    Orthofix Medical Inc.

     

     

     

     

    Date:

    April 7, 2025

    By:

    /s/ J. Andrés Cedrón

     

     

     

    J. Andrés Cedrón
    Chief Legal Officer

     


    Get the next $OFIX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OFIX

    DatePrice TargetRatingAnalyst
    1/27/2026$14.00Hold
    TD Cowen
    10/28/2025$22.00Buy
    Stifel
    1/22/2025$24.00Buy
    Canaccord Genuity
    11/8/2024$18.00 → $24.00Hold → Buy
    Stifel
    5/8/2024$15.00 → $20.00Neutral → Buy
    ROTH MKM
    10/20/2023$12.00Neutral
    ROTH MKM
    9/12/2023Buy → Neutral
    BTIG Research
    9/12/2023Buy → Hold
    Stifel
    More analyst ratings

    $OFIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Engine Capital Management, Lp bought $13,881 worth of shares (1,250 units at $11.11) (SEC Form 4)

    4 - Orthofix Medical Inc. (0000884624) (Issuer)

    7/7/25 5:43:59 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Director Bazaar Alan Lee bought $24,570 worth of shares (2,250 units at $10.92), increasing direct ownership by 8% to 30,983 units (SEC Form 4)

    4 - Orthofix Medical Inc. (0000884624) (Issuer)

    6/5/25 5:11:05 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Amendment: Large owner Engine Capital Management, Lp bought $1,231,000 worth of shares (100,000 units at $12.31) (SEC Form 4)

    4/A - Orthofix Medical Inc. (0000884624) (Issuer)

    5/14/25 4:34:50 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO Andrews Julie sold $70,074 worth of shares (4,873 units at $14.38), decreasing direct ownership by 8% to 58,039 units (SEC Form 4)

    4 - Orthofix Medical Inc. (0000884624) (Issuer)

    1/21/26 4:09:29 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    President & CEO Calafiore Massimo sold $300,955 worth of shares (19,397 units at $15.52), decreasing direct ownership by 8% to 217,237 units (SEC Form 4)

    4 - Orthofix Medical Inc. (0000884624) (Issuer)

    1/13/26 5:46:07 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    President, Global Orthopedics Fisher Patrick sold $28,363 worth of shares (1,996 units at $14.21), decreasing direct ownership by 6% to 30,116 units (SEC Form 4)

    4 - Orthofix Medical Inc. (0000884624) (Issuer)

    8/20/25 4:08:33 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Orthofix with a new price target

    TD Cowen initiated coverage of Orthofix with a rating of Hold and set a new price target of $14.00

    1/27/26 8:48:16 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Stifel resumed coverage on Orthofix with a new price target

    Stifel resumed coverage of Orthofix with a rating of Buy and set a new price target of $22.00

    10/28/25 7:09:19 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Canaccord Genuity initiated coverage on Orthofix with a new price target

    Canaccord Genuity initiated coverage of Orthofix with a rating of Buy and set a new price target of $24.00

    1/22/25 7:47:50 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Orthofix to Participate in Upcoming Investor Conferences

    Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that Massimo Calafiore, President and Chief Executive Officer, and Julie Andrews, Chief Financial Officer, will participate in the following investor conferences: Canaccord Genuity 2026 Musculoskeletal Conference - New Orleans, March 2, 2026, 9:30 am CT TD Cowen 46th Annual Health Care Conference - Boston, March 3, 2026, 11:10 am ET Interested parties can access the live and archived webcast of the presentations in the "Events & Presentations" section of the Orthofix Investor Relations Website at ir.orthofix.com. Internet Posting of Information Orthofix regularly shares important u

    2/10/26 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Fox Factory Announces Strategic Board Refresh

    Company to Appoint Two New Independent Directors and Form Transformation Committee Focused on Operational Excellence and Margin Improvement Company Enters into Cooperation Agreement with Engine Capital DULUTH, Ga., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Fox Factory Holding Corp. (Nasdaq: FOXF) ("Fox Factory" or the "Company"), a premium brand and a global leader in the design, engineering and manufacturing of performance-defining products and systems for customers worldwide, today announced that following constructive discussions with Engine Capital ("Engine Capital") regarding opportunities to enhance operational performance and profitability, the Company will be undertaking a strategic boar

    2/9/26 4:05:00 PM ET
    $FOXF
    $OFIX
    Motor Vehicles
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

    Orthofix to Report Fourth Quarter and Full-Year 2025 Financial Results

    Company to Host Conference Call on Tuesday, February 24, 2026, at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its fourth quarter and full-year 2025 financial results on Tuesday, February 24, 2026, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 2236604. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. In

    2/3/26 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    SEC Filings

    View All

    SEC Form 10-Q filed by Orthofix Medical Inc.

    10-Q - Orthofix Medical Inc. (0000884624) (Filer)

    11/4/25 9:01:22 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Orthofix Medical Inc. (0000884624) (Filer)

    11/4/25 7:02:23 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Orthofix Medical Inc.

    SCHEDULE 13D/A - Orthofix Medical Inc. (0000884624) (Subject)

    9/25/25 8:03:52 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    Leadership Updates

    Live Leadership Updates

    View All

    Fox Factory Announces Strategic Board Refresh

    Company to Appoint Two New Independent Directors and Form Transformation Committee Focused on Operational Excellence and Margin Improvement Company Enters into Cooperation Agreement with Engine Capital DULUTH, Ga., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Fox Factory Holding Corp. (Nasdaq: FOXF) ("Fox Factory" or the "Company"), a premium brand and a global leader in the design, engineering and manufacturing of performance-defining products and systems for customers worldwide, today announced that following constructive discussions with Engine Capital ("Engine Capital") regarding opportunities to enhance operational performance and profitability, the Company will be undertaking a strategic boar

    2/9/26 4:05:00 PM ET
    $FOXF
    $OFIX
    Motor Vehicles
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

    Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. "We are delighted to welcome Maria to our Board of Directors," said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. "She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional m

    1/9/26 7:00:00 AM ET
    $AVNS
    $HYPR
    $OFIX
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    Orthofix Announces Appointment of Vickie Capps to Board of Directors

    Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the appointment of Vickie Capps to the Company's Board of Directors, effective March 11, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250312538957/en/Vickie Capps (Photo: Business Wire) "Vickie brings a wealth of experience to our Board at a pivotal stage for Orthofix," said Michael Finegan, Chairman of Orthofix. "Her expertise in global business operations, strategic business development and corporate finance will provide the Board with a tremendously valuable perspective as we seek to deliver profitable growth and significa

    3/12/25 8:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    Financials

    Live finance-specific insights

    View All

    Orthofix to Report Fourth Quarter and Full-Year 2025 Financial Results

    Company to Host Conference Call on Tuesday, February 24, 2026, at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its fourth quarter and full-year 2025 financial results on Tuesday, February 24, 2026, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 2236604. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. In

    2/3/26 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix Reports Third Quarter 2025 Financial Results

    Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the third quarter ended September 30, 2025, narrowed its full-year 2025 net sales guidance while maintaining the midpoint, and raised the low end of its adjusted EBITDA guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6™ product lines. Highlights Third quarter 2025 net sales of $205.6 million, including sales from M6 artificial cervical and lumbar discs, and pro forma net sales of $203.4 million, excluding sales from M6 discs, representing an increase of 5% on a reported basis and 6% on a

    11/4/25 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix to Report Third Quarter 2025 Financial Results

    Company to Host Conference Call on Tuesday, November 4, 2025, at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its third quarter 2025 financial results on Tuesday, November 4, 2025, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 5112586. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Posting of

    10/14/25 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Orthofix Medical Inc.

    SC 13G/A - Orthofix Medical Inc. (0000884624) (Subject)

    11/14/24 5:20:27 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Orthofix Medical Inc.

    SC 13G - Orthofix Medical Inc. (0000884624) (Subject)

    11/13/24 5:03:21 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Orthofix Medical Inc. (Amendment)

    SC 13D/A - Orthofix Medical Inc. (0000884624) (Subject)

    4/22/24 5:00:33 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care